ID   LREX'
AC   CVCL_UD76
SY   LnCaP/AR Resistant to Enzalutamide Xenograft derived
DR   cancercelllines; CVCL_UD76
DR   Wikidata; Q95983040
RX   PubMed=24315100;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:68534; Enzalutamide (Xtandi; MDV-3100).
CC   Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: Metastatic; Left supraclavicular lymph node; UBERON=UBERON_8480056.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0395 ! LNCaP
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 13-11-18; Last updated: 05-10-23; Version: 9
//
RX   PubMed=24315100; DOI=10.1016/j.cell.2013.11.012;
RA   Arora V.K., Schenkein E., Murali R., Subudhi S.K., Wongvipat J.,
RA   Balbas M.D., Shah N., Cai L., Efstathiou E., Logothetis C.J.,
RA   Zheng D.-Y., Sawyers C.L.;
RT   "Glucocorticoid receptor confers resistance to antiandrogens by
RT   bypassing androgen receptor blockade.";
RL   Cell 155:1309-1322(2013).
//